Browse >
Home / Archive: December 2008
A team of scientists from the US and China have discovered that grape-seed extract kills laboratory leukemia cells by making them commit suicide, thus showing the potential value of natural compounds in the treatment of cancer.
US researchers studying the effect of beta carotene, vitamin C and vitamin E, either singly or in combination, on over 7,000 women found the supplements did not reduce their risk of getting cancer compared to women who did not take the supplements. However an expert who reviewed the study said that while the overall message was there was no link, it uncovered some interesting evidence that should not be overlooked.
Cancer Research UK scientists have discovered for the first time that stem cells could be the root cause of bowel cancer, according to a study published in Nature* today (Wednesday). Scientists at Cancer Research UK's Beatson Institute for Cancer Research in Glasgow, Cardiff University and the Hubrecht Institute in the Netherlands - isolated stem cells in the bowels of mice and 'knocked out' a gene called APC from them.
Scientists in Japan are reporting an advance toward using a natural disease-fighting protein in pills or syrups that patients can take by mouth rather than injection. Their study is the first to show that coating the protein with a polymer material already in wide medical use can increase its absorption by the intestine. The research appears in the current issue of ACS' Bioconjugate Chemistry, a monthly journal.
University of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection. Results of the study are published in the Dec. 27, 2008, edition of the journal Transplantation.
While examining patterns of DNA modification in lung cancer, a team of international researchers has discovered what they say is a surprising new mechanism. They say that "silencing" of a single gene in lung cancer led to a general impairment in genome-wide changes in cells, contributing to cancer development and progression. In the January 1, 2009, issue of
An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky. They found that within 24 hours, 76 percent of leukemia cells had died after being exposed to the extract. The investigators, who report their findings in the January 1, 2009, issue of
WASHINGTON -- Hospitals in about a dozen states are testing whether some simple steps, such as arm-strengthening exercises, could reduce the risk of one of breast cancer's troubling legacies - the painful and sometimes severe arm swelling called lymphedema. Lymphedema has long been a neglected side effect of cancer surgery and radiation: Many women say they never were warned, even though spotting this problem early improves outcomes. And while less invasive surgical techniques mean fewer breast cancer patients today than just a few years ago should face lymphedema, it's a lingering threat for tens of thousands of survivors because it can strike two decades after their tumour was treated. "I have ladies tell me the lymphedema is muc...
CAMBRIDGE, Mass. -- Molecular Insight Pharmaceuticals, Inc. announced today the publication of a preclinical study describing the synthesis and initial evaluation of two series of radiolabeled small molecules that target prostate-specific membrane antigen (PSMA), a validated molecular marker for prostate cancer. The lead compounds, MIP-1072 and MIP-1095, demonstrated high affinity and specific binding to PSMA on human prostate cancer cells, and the radiolabeled analogs provide the foundation for the Company's Trofex prostate cancer molecular imaging program, which is currently undergoing an exploratory Phase 1 clinical trial in patients with histological confirmed prostate cancer and evidence of recurrent disease. The go...
MEMPHIS, Tenn. -- GTx, Inc. today announced the submission of a New Drug Application with the U.S. Food and Drug Administration (FDA) for toremifene 80 mg, an oral selective estrogen receptor modulator (SERM), for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy (ADT). "ADT has helped improve survival for men with advanced prostate cancer. Unfortunately, ADT may cause unintended serious estrogen deficiency side effects, such as a high risk of fractures, which can shorten survival," said Dr. Mitchell Steiner, CEO of GTx. "If approved, toremifene 80 mg could become the first cancer care agent for the prevention of fractures in men receiving ADT." Ipsen Group has licensed Europe...
Next Page »
